Dr Alicja Jasinska Piadlo (@APiadlo) header
Dr Alicja Jasinska Piadlo (@APiadlo) profile picture

Cardiology ST6, PhD, AI in Heart Failure @SouthernHSCT funded by @HSC_NI R&D, @irishcardiacsoc Ed.Committee @BSHeartFailure, Pole in NI

Belfast
Joined July 2018
What if we've been defining "normal" incorrectly? A single reference value may not reflect every patient. Sex-specific biology. Pregnancy. Menopause. Ethnicity. Life-course cardiovascular adaptation. Perhaps the future of cardiac imaging isn't better images—it's better interpretation. Maybe the most important question is no longer: "Is this normal?" But rather: "Normal for whom?" How should cardiovascular imaging evolve in the era of precision medicine? #Cardiology #EchoFirst #CardiacImaging #PrecisionMedicine #WomensHeartHealth @kenyacardiacs
3
3
136
Dr Alicja Jasinska Piadlo retweeted
Time-dependent outcomes in myocarditis and inflammatory #cardiomyopathy patients treated with the IL-1 receptor antagonist #Anakinra academic.oup.com/eurjhf/adva… #EJHF @HanCardiomd @AmrAbdin10 @GiuseppeGalati_
23
47
3,657
Dr Alicja Jasinska Piadlo retweeted
Prevention of #HeartFailure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors academic.oup.com/eurjhf/adva… @ARakisheva #EJHF @escardio @HanCardiomd @AmrAbdin10 @GiuseppeGalati_
13
23
1,494
Dr Alicja Jasinska Piadlo retweeted
🗞️ Risk models for sudden cardiac death in cardiomyopathies: clinical, methodological and ethical challenges @ESC_Journals @GiuseppeGalati_ @AmrAbdin10 @HanCardiomd bit.ly/4f06nA7
10
1
29
8,629
Dr Alicja Jasinska Piadlo retweeted
🔥 Risk models for sudden cardiac death in cardiomyopathies: clinical, methodological and ethical challenges ✅The absence of a unified approach across cardiomyopathy subtypes un­derscores both their biological heterogeneity and the complexity of modelling #SCD risk in cardiomyopathies. ✅The field of risk modelling would benefit from more harmonized approaches to risk calculator de­velopment, including shared endpoint definitions & consistent model­ ling strategies, as well as models that integrate time-varying inputs, phenotype–genotype interactions, and include multi-ethnic calibration. ✅Disease-specific scores should be supplemented with genotype and deep-phenotype data, including clinical details, ECG features, arrhyth­mia burden, and advanced imaging parameters, when available. bit.ly/4f06nA7 🫀 @HFUAcademy 🍀 heartfailureuniversalacademy… @EJHFEiC @HFA_President @gpontone1 @chiarabd @MicheleEmdin @AmrAbdin10 @KTamirisaMD @DrRajivsankar @JBauersachsMD @robmentz @TomLuscher @AndrewJSauer @DrMarthaGulati @FedericaFogacci @afgcicero @glimongelli @IacopoOlivotto @HanCardiomd @GMCRosano @SeguraCardio @ShelleyZieroth @chiarabd @iamritu @cristinagavina @FeliceGragnano @rahatheart1 @gpontone1 @stefanocarugo @AnastasiaSMihai @radcliffeCARDIO @GCFmeeting
🗞️ Risk models for sudden cardiac death in cardiomyopathies: clinical, methodological and ethical challenges @ESC_Journals @GiuseppeGalati_ @AmrAbdin10 @HanCardiomd bit.ly/4f06nA7
2
15
2
47
6,314
Dr Alicja Jasinska Piadlo retweeted
2
2
287
Dr Alicja Jasinska Piadlo retweeted
🫀🔥 When myocarditis is not just myocarditis… A new study by sheds light on a critical and often under-recognised entity: desmosomal “hot-phase” cardiomyopathy (HPC). 💡 Why does this matter? Because HPC can mimic acute myocarditis, but carries a much higher arrhythmic risk and different clinical implications. 🔍 Key insights from the study: 👉 Patients with desmosomal HPC are often: • 👩‍⚕️ Young and female • 🧬 Carriers of desmosomal gene variants (mostly DSP) 👉 Compared to classic myocarditis, HPC shows distinctive “red flags”: 🧾 Clinical clues • Family history of cardiomyopathy / sudden cardiac death • Recurrent troponin elevations (“hot-phase” relapses) 🧲 Imaging clues (CMR) • Ring-like late gadolinium enhancement (LGE) • Right ventricular involvement • Persistent or progressive LGE • Incomplete recovery of LV function ⚡ Electrical clues • Low QRS voltages • High arrhythmic burden • Ventricular arrhythmias at a young age (<45 yrs) 📊 A practical takeaway A simple combination of: ➡️ Ring-like LGE ➡️ RV involvement ➡️ Family history 🎯 Achieved ~93% diagnostic accuracy in identifying HPC. 🚨 Clinical implication Recognising these red flags early can: ✔️ Prompt genetic testing ✔️ Improve risk stratification ✔️ Prevent life-threatening arrhythmias and adverse outcomes 💭 Bottom line: Not all myocarditis is inflammatory. Some cases are the first manifestation of a genetic cardiomyopathy. 👉 We need to think beyond the diagnosis and look for the phenotype. #Cardiology #Cardiomyopathy #Myocarditis #CMR #CardiacMRI #Arrhythmia #Genetics #PrecisionMedicine #DSP #ACM #HeartDisease #MedicalResearch #CardioTwitter doi.org/10.1161/JAHA.125.044…
1
11
1
54
2,894
Dr Alicja Jasinska Piadlo retweeted
Biomarkers are everywhere—but how many actually matter? 🧪 Most fail when it counts. This #JACC paper separates hype from reality: jacc.org/doi/10.1016/j.jacc.… @JavedButler1 @LauraDemichieli
1
40
1
119
9,732
Dr Alicja Jasinska Piadlo retweeted
🔴Disease Prognosis & Progression in TTR Amyloidosis: JACC: State-of-the-Art Review @JACCJournals #Cardiology #ATTR #Amyloidosis #CardioEd #FOAMed
1
22
57
3,454
Dr Alicja Jasinska Piadlo retweeted
Published today, Brain Health Across the Life Span: A Framework for Future Studies A Scientific Statement from the American Heart Association. 📷 Recommendations to optimize brain health
5
60
5
117
11,555
Dr Alicja Jasinska Piadlo retweeted
❤️ SGLT2 inhibitors are not “diabetes drugs” anymore...They are hemodynamic drugs!! We’ve all seen the shift in guidelines. But many still think: 👉 “They lower glucose → good for diabetics” 🚨 That’s outdated thinking. 📚 A recent narrative review clearly reinforces what we’re already seeing in practice: ⚙️ SGLT2 inhibitors fundamentally reshape hemodynamics 🧪 At the kidney level: ▪️ ↓ Sodium reabsorption ▪️ ↑ Natriuresis + osmotic diuresis ▪️ ↓ Glomerular pressure (via tubuloglomerular feedback) 👉 Translation: ✔️ Less hyperfiltration ✔️ Slower CKD progression ✔️ Better renal protection ❤️ At the cardiovascular level: 💧 Preload reduction 👉 Interstitial fluid loss > intravascular depletion ✔️ Decongestion without aggressive hypotension 🫀 Afterload reduction 👉 ↓ Arterial stiffness 👉 ↓ systemic vascular resistance 📉 Blood pressure effect 👉 Modest but consistent (~3–4 mmHg systolic) ✔️ Without reflex tachycardia ✔️ Without RAAS overactivation 🔥 The real magic: 👉 Unlike loop diuretics: 🟥 Loop diuretics → intravascular depletion → neurohormonal activation 🟩 SGLT2 inhibitors → interstitial unloading → hemodynamic stability 📊 Clinical outcomes back it up ✔️ ↓ HF hospitalization ✔️ ↓ CV mortality ✔️ ↓ CKD progression (~44% in some cohorts) 🎯 The paradigm shift These drugs are: ❌ Not just antidiabetics ❌ Not just mild diuretics ✔️ They are cardio-renal modulators 💡 Clinical takeaway 👉 Think SGLT2 inhibitors when you think: ▪️ Heart failure (HFrEF + HFpEF) ▪️ CKD (with or without diabetes) ▪️ Cardio-renal syndrome 🧠 And most importantly: 👉 Use them early 👉 Not as “last-line add-ons” 🔥 The future of heart failure is not just inotropes and diuretics. It’s metabolic-hemodynamic modulation. 💬 Your experience: 👉 Are you already using SGLT2 inhibitors systematically in non-diabetic HF patients? 👉 Or still waiting for “perfect indications”? 📚 Reference Brata, R., etc al. Healthcare, 12(23), 2464. doi.org/10.3390/healthcare12…⁠
4
88
257
13,903
Thyroid dysfunction and cardiovascular disease. A State-of-the-Art review in #EHJ 👉 ow.ly/I7Jx50YQTxc @RoccoMontone @ehj_ed
1
48
139
9,418
This statement!!!!! Thanks @JCardFail @HFSA for this amazing document to help us all understand #HFmEF It’s a new era in #heartfunction #functionnotfailure
HF with mildly reduced EF (HFmrEF) sits between HFrEF & HFpEF; where does it truly belong? A new HFSA Scientific Statement examines its epidemiology & pathophysiology & provides a comprehensive management framework for this understudied HF phenotype🫀 🔗 bit.ly/4sKAy21
1
21
1
59
11,022
Dr Alicja Jasinska Piadlo retweeted
Cardiac Resynchronization Therapy A Review Cardiac dyssynchrony due to conduction system disease occurs in 20% to 30% of patients with HF and systolic dysfunction. Cardiac resynchronization therapy restores synchronous ventricular activation in patients with HF, reduced LVEF, and left bundle-branch block, or in those requiring chronic ventricular pacing, and may improve LV function, decrease HF hospitalizations, and reduce mortality. @JAMA_current @gcfmd @SJGreene_md @hvanspall @ShelleyZieroth @GianluSava @hfcollaboratory @HFA_President @ankeetbhatt ja.ma/4tTXfSR
2
9
611
Dr Alicja Jasinska Piadlo retweeted
US physician attrition is rising, hitting women and rural doctors hardest. Systemic pressures and not just burnout drive exits, threatening healthcare access, especially in already underserved areas. Structural change is needed to sustain the workforce. kevinmd.com/2026/01/physicia…
5
11
481
Another evidence of women being underrepresented in clinical trials. It’s time to close the gap.
In our latest @JACCJournals article, we show that IVI-guided PCI reduces MACE in both men & women—with no sex interaction. Yet, women remain underrepresented in IVI trials (23.9%). It’s time to close the gap. jacc.org/doi/10.1016/j.jacad…
209
Dr Alicja Jasinska Piadlo retweeted
Research shows MRI scans can detect heart risk up to 10 years earlier, even in people with “normal” heart function. For women, cholesterol in the high-normal range was the key risk driver, underscoring the need for earlier, sex-specific intervention. dundee.ac.uk/stories/mri-sca…
1
7
1
16
1,114
Dr Alicja Jasinska Piadlo retweeted
This study indicates that photon-counting detector computed tomography (PCD-CT) provides high diagnostic accuracy for detecting in-stent restenosis in patients with prior coronary stents. This suggests that PCD-CT may be reliably used to evaluate suspected obstructive coronary artery disease in both stented and unstented coronary segments. eurointervention.pcronline.c…
2
21
100
7,687
Dr Alicja Jasinska Piadlo retweeted
Most Updated Global Burden of Cardiovascular Disease now out in @JACCJournals 80% (!) of CV disease burden is attributable to modifiable RFs Top modifiable risks in 2023: ⚠️ High systolic BP ⚠️ Dietary risks ⚠️ High LDL cholesterol ⚠️ Air pollution 🔗 jacc.org/doi/10.1016/j.jacc.…
3
63
1
154
10,763